Illumina, Inc. (ILMN)
NASDAQ: ILMN · Real-Time Price · USD
131.68
-3.32 (-2.46%)
At close: Nov 20, 2024, 4:00 PM
131.83
+0.15 (0.11%)
After-hours: Nov 20, 2024, 4:13 PM EST

Company Description

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally.

It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test.

In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications.

The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.

It markets and distributes its products directly to customers, as well as through life-science distributors.

Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Illumina, Inc.
Illumina logo
Country United States
Founded 1998
IPO Date Jul 28, 2000
Industry Diagnostics & Research
Sector Healthcare
Employees 13,360
CEO Jacob Thaysen

Contact Details

Address:
5200 Illumina Way
San Diego, California 92122
United States
Phone 858 202 4500
Website illumina.com

Stock Details

Ticker Symbol ILMN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001110803
CUSIP Number 452327109
ISIN Number US4523271090
Employer ID 33-0804655
SIC Code 3826

Key Executives

Name Position
Jakob Wedel Chief Strategy and Corporate Development Officer and Chief Executive Officer Chief of Staff
Jacob Thaysen Ph.D. Chief Executive Officer and Director
Carissa L. Rollins Chief Information Officer
Charles E. Dadswell Esq. Advisor
Stephanie Campos President
Kevin Carl Pegels Chief of Global Operations
Scott Ericksen Vice President and Chief Accounting Officer
Dr. Steven Barnard Ph.D. Chief Technology Officer
Sallilyn Schwartz Vice President of Investor Relations
Scott Davies Interim General Counsel and Secretary

Latest SEC Filings

Date Type Title
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 6, 2024 10-Q Quarterly Report
Nov 4, 2024 8-K Current Report
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 15, 2024 144 Filing
Oct 3, 2024 8-K Current Report
Sep 9, 2024 8-K Current Report
Sep 5, 2024 8-K Current Report
Sep 5, 2024 424B2 Prospectus
Sep 4, 2024 FWP Free Writing Prospectus